ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "proteomics"

  • Abstract Number: 2581 • ACR Convergence 2023

    Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies

    Samir Rachid Zaim1, Adam Savage1, Mark Gillespie1, Christy Bennett1, lynne Becker1, LauraKay Moss2, Marie Feser2, Jess Edison3, Ted R Mikuls4, Michael Holer2, kevin Deane2 and Xiao-Jun Li1, 1Allen Institute for Immunology, Seattle, WA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3Walter Reed Military Medical Center, Bethesda, MD, 4Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…
  • Abstract Number: 0962 • ACR Convergence 2023

    Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma

    Irene Choi1, Courtney Yu2, Francesco Boin1, Elizabeth Volkmann3, Stephanie Stanford2 and Nunzio Bottini4, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2University of California San Diego, San Diego, CA, 3University of California Los Angeles, Los Angeles, CA, 4University of California, San Francisco, CA

    Background/Purpose: Scleroderma (SSc) is a chronic autoimmune and rheumatic disease characterized by varying levels of tissue fibrosis in the skin and other internal organs. It…
  • Abstract Number: 2601 • ACR Convergence 2023

    Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning

    kevin cunningham1, Jaeyun Sung2, Benjamin Hur2, VINOD GUPTA2, Matthew Koster2, Cornelia M. Weyand3, David Cuthbertson4, Nader Khalidi5, Curry Koening6, Carol Langford7, Carol McAlear8, Paul Monach9, Larry Moreland10, Christian Pagnoux11, Rennie Rhee8, Philip Seo12, Peter Merkel8 and Kenneth Warrington2, 1University of Minnesota, Minneapolis, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic School of Medicine and Stanford University, Rochester, MN, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6University of Texas Dell Medical School, Austin, TX, 7Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Philadelphia, PA, 9VA Boston Healthcare System, Boston, MA, 10University of Colorado, Denver, CO, 11Mount Sinai Hospital, Toronto, ON, Canada, 12Johns Hopkins University, Baltimore, MD

    Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
  • Abstract Number: 1608 • ACR Convergence 2023

    Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

    Ayesha Butt1, Rolando Garcia Milian1, George Goshua1, Sean Gu1, Eugenia Chock2, Valentina Restrepo1, John Hwa1, Hyung Chun1, H Michael Belmont3, Kello Nina4, D. Ware Branch5, Michelle Petri6, Jason Knight7, Rohan Willis8, Maria Laura Bertolaccini9, Doruk Erkan10, Alfred lee1, Anish Sharda1 and Alexander Pine11, 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, Greenwich, CT, 3NYU School of Medicine, New York, NY, 4Northwell Health, Brooklyn, NY, 5University of Utah, Salt Lake City, UT, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7University of Michigan, Ann Arbor, MI, 8University of Texas Medical Branch, Galveston, TX, 9King's College London, London, United Kingdom, 10Hospital for Special Surgery, New York, NY, 11VA Connecticut/Yale School of Medicine, West Haven, CT

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
  • Abstract Number: 1633 • ACR Convergence 2023

    Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease

    Stephanie Finzel1, Andrea Grioni2, Benjamin A Fisher3, Athena S Papas4, Alexandre Avrameas2, Danny Tuckwell2, Jonas Zierer2, Celine Rauld2, Valeria De Luca2, Enrico Ferrero2, Andre Nogueira da Costa2, Rainer Hillenbrand2, Isabelle Isnardi2 and Wolfgang Hueber2, 1Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3University of Birmingham, Birmingham, United Kingdom, 4Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA

    Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
  • Abstract Number: 1637 • ACR Convergence 2023

    IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity

    Helena Achten1, Liselotte Deroo2, Kristel De Boeck3, Matthias Jarlborg1, Tine Decruy1, Joke Deprez1, Emilie Dumas1, Dirk Elewaut4 and isabelle peene5, 1Ghent University, Ghent, Belgium, 2Ghent University, Gent, Belgium, 3Ghent University Hospital, Ghent, Belgium, 4Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5University Hospital Ghent, Ghent, Belgium

    Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…
  • Abstract Number: 0020 • ACR Convergence 2023

    The Inflammatory Proteome in Sjögren’s Syndrome Identifies New Biomarkers and Relevant Clinical Subgroups

    José Miguel Sequí-Sabater1, Carlos Perez-Sanchez2, Clarissa Meoni3, Tomás Cerdó-Ráez4, Maria del Carmen Abalos-Aguilera5, Desiree Ruiz Vilchez5, Francisco Cepas4, Nuria Barbarroja6, Alejandro Escudero7, Mª Angeles Aguirre8, Chary Lopez-Pedrera9 and Lorenzo Beretta10, 1Agencia Valenciana de Salut/ Hospital Universitari de la Ribera/ Unitat de Reumatología, Gandía, Spain, 2IMIBIC, Córdoba, Spain, 3Ospedale Policlinico di Milano, Milan, Italy, 4Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, 5Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, 6University of Cordoba, Córdoba, Spain, 7SAS, Córdoba, Spain, 8Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 9IMIBIC - Reina Sofia Hospital, Córdoba, Spain, 10Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy

    Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterised by glandular involvement of the eye and salivary glands, leading to xerostomia and xerophthalmia. In…
  • Abstract Number: 1696 • ACR Convergence 2023

    Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis

    Michael A. Smith1, Dominic Sinibaldi2, Saifur Rahman1, Chia-Chien Chiang2, Anna M. Hansen1, Jill Henault1, Carlos P. Roca3, Shu Wang1, Kamelia Zerrouki1, Rebecca Filippi1, Christopher Groves1, Zerai Manna4, Jun Chu4, Michael Davis4, sarthak gupta4, Christopher Morehouse1, Melissa De los Reyes1, Rachel Ettinger1, Roland Kolbeck1, Mariana Kaplan5, Miguel A. Sanjuan1, Richard M. Siegel6, sarfaraz Hasni4 and Kerry A. Casey1, 1BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Data Science and AI, AstraZeneca, Gaithersburg, MD, 3Data Science and AI, AstraZeneca, Cambridge, United Kingdom, 4Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 5Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 6Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
  • Abstract Number: 0023 • ACR Convergence 2023

    Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis

    Avital Baniel1, Mariko Ogawa-Momohara2, Muhammad Bashir3, Rachita Pandya1, Julianne Kleitsch1, Felix Chin4, Ming-Lin Liu1 and Victoria P. Werth5, 1University of Pennsylvania, Philadelphia, PA, 2Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 5University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Extracellular vesicles (EVs) have been implicated in autoimmune disease pathogenesis. Plasma-derived DNA containing EVs have been shown to induce STING-mediated proinflammatory responses in dermatomyositis…
  • Abstract Number: 1698 • ACR Convergence 2023

    High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis

    Huihua Ding, Yiwei Shen, Min Dai and Nan Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: Navigating the molecular complexity of lupus nephritis (LN), a heterogeneous autoimmune disorder, poses challenges to biomarker discovery. This study addresses these challenges through an…
  • Abstract Number: 0659 • ACR Convergence 2022

    Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets

    Joshua Reynolds1, Chandra Mohan2, Yaxi Li2 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2University of Houston, Houston, TX

    Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…
  • Abstract Number: 0660 • ACR Convergence 2022

    Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study

    Audrey Hagiwara1, Moumita Bose1, Aleksandr Stotland1, Aleksandra Binek1, Koen Raedschelders1, Janet Wei1, C. Noel Bairey Merz1, Sarah Parker1, Jennifer Van Eyk1, Daniel Wallace1, Mariko Ishimori2 and Caroline Jefferies1, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Cedars-Sinai Health System, Los Angeles, CA

    Background/Purpose: Cardiovascular disease (CVD) is a significant cause of mortality in patients with SLE. While obstructive coronary artery disease (CAD) is a leading cause of…
  • Abstract Number: 0909 • ACR Convergence 2022

    Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera1, Tomás Cerdó2, Maria Luque-Tevar3, Pilar Font1, Montserrat Romero-Gomez2, Desiree Ruiz-Vilchez4, Sara Remuzgo-Martinez5, Raquel Lopez Mejias6, María Carmen Ábalos-Aguilera7, Rafaela Ortega-Castro1, José Perez-Venegas8, Mª Dolores Ruiz-Montesinos8, Carmen Dominguez8, Carlos Rodriguez-Escalera9, Carmen Romero-Barco9, Antonio Fernandez-Nebro10, Natalia Mena Vazquez10, Jose Luis Marenco11, Julia Uceda Montañez11, Charo Santos12, Nuria Barbarroja1, Mª Angeles Aguirre13, Alejandro Escudero-Contreras2, Eduardo Collantes1, Miguel Ángel González-Gay14 and Carlos Pérez-Sánchez1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 3IMIBIC, Córdoba, Spain, 4Reina Sofia University Hospital, Cordoba, Cordoba, Spain, 5Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6IDIVAL, Santander, Spain, 7Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, 8Virgen Macarena University Hospital, Sevilla, Spain, 9Virgen de la Victoria Hospital, Málaga, Spain, 10Regional University Hospital of Málaga, Málaga, Spain, 11Virgen de Valme University Hospital, Sevilla, Spain, 12Virgen de Valme University Hospital, Málaga, Spain, 13Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, 14Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…
  • Abstract Number: 0975 • ACR Convergence 2022

    Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE

    Paul Newcombe1, Richard A. Furie2, Yoshiya Tanaka3, Wendy White4, Dominic Sinibaldi4, Philip Brohawn4, Mark Lazarus1, Nicola Ferrari1, Raj Tummala4, Hussein Al-Mossawi1, Andre Nogueria da Costa5, Daniel Muthas5 and Madhu Ramaswamy4, 1AstraZeneca, Cambridge, United Kingdom, 2Northwell Health, Great Neck, NY, 3University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 4AstraZeneca, Gaithersburg, MD, 5AstraZeneca, Gothenburg, Sweden

    Background/Purpose: SLE has been associated with expression of type I IFN gene signatures (IFNGS).1 Anifrolumab, a monoclonal antibody binding IFN receptor subunit 1, inhibits downstream…
  • Abstract Number: 1087 • ACR Convergence 2022

    Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach

    Zachary Wallace1, Amit Joshi1, Xiaoqing Fu1, Claire Cook1, yuqing zhang2 and Hyon Choi3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Quincy, MA, 3MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: ANCA-associated vasculitis (AAV) is associated with excess morbidity and mortality. Identifying novel biomarkers may reveal new therapeutic targets and clinically useful biomarkers of disease…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology